The Globe and Mail reports in its Friday, Feb. 7, edition that Stifel analyst Justin Keywood, citing "near term headwinds as developments continue to be monitored," has downgraded his recommendation for Medexus Pharmaceuticals to "hold" from "buy." The Globe's David Leeder writes in the Eye On Equities column that Mr. Keywood slashed his share target by $2.55 to $3.45. Analysts on average target the shares at $6.15. Mr. Keywood says in a note: "Medexus Pharmaceuticals is up almost 40 per cent in LTM [last 12 months] and peaked at $5/share, vs. $2 in Nov., following the FDA approval of GRAFAPEX (treosulfan), an important treatment for allogeneic hematopoietic stem cell transplantation. However, initial pricing assumptions of $25k (U.S.)/treatment appears optimistic, including a recent pharmacoeconomic review. The pricing would also be multiple times higher than in Canada and the UK and likely a pricing factor. There is also generic risk in the base business with Rupall (20 per cent of sales), losing exclusivity late last month as a negative Health Canada setback for Terbinafine (nail fungus) was disclosed today."